Korea Investment CORP Buys 46,317 Shares of Edwards Lifesciences Corporation $EW

Korea Investment CORP grew its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 10.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 510,890 shares of the medical research company’s stock after buying an additional 46,317 shares during the period. Korea Investment CORP’s holdings in Edwards Lifesciences were worth $39,732,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. True Wealth Design LLC boosted its position in shares of Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 259 shares during the period. Rakuten Securities Inc. increased its holdings in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares during the period. Hantz Financial Services Inc. increased its holdings in Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after acquiring an additional 164 shares during the period. Steigerwald Gordon & Koch Inc. purchased a new stake in Edwards Lifesciences in the 3rd quarter worth approximately $30,000. Finally, Strengthening Families & Communities LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter worth approximately $34,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,885,571.40. This trade represents a 4.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total value of $2,012,160.00. Following the completion of the sale, the vice president owned 21,266 shares in the company, valued at approximately $1,782,941.44. This represents a 53.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 71,444 shares of company stock worth $6,035,269. 0.34% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on EW shares. Canaccord Genuity Group set a $87.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Wednesday, December 17th. Citigroup reiterated a “buy” rating and issued a $101.00 price objective (up from $96.00) on shares of Edwards Lifesciences in a research report on Thursday, December 11th. Robert W. Baird set a $90.00 price objective on Edwards Lifesciences in a research note on Monday, January 12th. TD Cowen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Friday, January 9th. Finally, Stifel Nicolaus set a $110.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $96.14.

Edwards Lifesciences Trading Up 3.2%

Shares of EW opened at $84.21 on Tuesday. The stock has a market capitalization of $48.91 billion, a P/E ratio of 46.02, a PEG ratio of 2.13 and a beta of 0.93. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. The firm has a fifty day simple moving average of $82.51 and a two-hundred day simple moving average of $81.49.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The firm had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. Edwards Lifesciences’s revenue was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.